Boston Scientific (BSX) to Update on Three co-Primary Endpoints for PREVAIL at ACoC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Boston Scientific (BSX) 'Surprises' ACC with WATCHMAN Presentation Plans
March 5, 2013 12:34 PM ESTBoston Scientific (NYSE: BSX) said on Monday that is planned to present "acute procedural safety results of the PREVAIL clinical trial that evaluates the WATCHMAN left atrial appendage closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy" at the 62nd Annual... More
